Safety of fractionated dose of rituximab in renal failure patients receiving hemodialysis.
Ostronoff
F
F
Ostronoff
M
M
Florêncio
R
R
Matias
C
C
Souto Maior
A P
AP
Domingues
M C
MC
Calixto
R
R
Sucupira
A
A
Matias
K
K
Tagliari
C
C
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D006435:Renal Dialysis / Q000379:methods*; D051437:Renal Insufficiency / Q000188:drug therapy*; D000069283:Rituximab; D020246:Venous Thrombosis / Q000150:complications
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab